Foreign Media: Eli Lilly, a major US pharmaceutical company, announced that it will add an additional $3 billion in investment in China over the next decade, bringing its total investment in China close to $6 billion, to strengthen local supply chains and manufacturing capabilities.
This investment focuses on establishing a domestic production and supply system for oral solid dosage forms, including building large-scale production capacity for its first-in-class oral small-molecule GLP-1 receptor agonist orforglipron, which is under application for the treatment of type 2 diabetes and obesity.
Eli Lilly will also invest $200 million in the domestic contract research and development organization Kanglong Chemical to support its technological capability development. This move comes as competition in the Chinese GLP-1 market intensifies, with Novo Nordisk's semaglutide patent expiring this month, leading to a surge of generic drugs entering the market.
Original article: toutiao.com/article/1859380882708487/
Statement: The article represents the personal views of the author.